Matthew Sykes
Stock Analyst at Goldman Sachs
(4.05)
# 542
Out of 5,140 analysts
210
Total ratings
53.74%
Success rate
11.19%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $17.01 | -70.61% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $5.52 | -45.65% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $22.68 | -71.34% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $51.95 | -13.38% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.84 | +36.99% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $43.65 | +9.97% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $18.98 | -10.43% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $184.87 | -13.45% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $12.69 | -21.20% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $116.53 | +7.27% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $12.21 | +14.66% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $242.05 | -0.85% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $20.83 | +24.82% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $226.77 | -25.03% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $115.75 | -51.62% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $100.04 | -20.03% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $2.42 | -38.02% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $242.78 | -21.74% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $2.18 | -19.72% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.84 | +10.82% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $43.30 | -14.55% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $102.48 | -36.57% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $241.40 | +3.56% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $7.05 | +240.43% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,442.93 | -9.91% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $9.78 | +22.70% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $636.30 | +0.58% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $139.77 | +3.74% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $55.66 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $17.01
Upside: -70.61%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $5.52
Upside: -45.65%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $22.68
Upside: -71.34%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $51.95
Upside: -13.38%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.84
Upside: +36.99%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $43.65
Upside: +9.97%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $18.98
Upside: -10.43%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $184.87
Upside: -13.45%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $12.69
Upside: -21.20%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $116.53
Upside: +7.27%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.21
Upside: +14.66%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $242.05
Upside: -0.85%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $20.83
Upside: +24.82%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $226.77
Upside: -25.03%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $115.75
Upside: -51.62%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $100.04
Upside: -20.03%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $2.42
Upside: -38.02%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $242.78
Upside: -21.74%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $2.18
Upside: -19.72%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.84
Upside: +10.82%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $43.30
Upside: -14.55%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $102.48
Upside: -36.57%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $241.40
Upside: +3.56%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $7.05
Upside: +240.43%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,442.93
Upside: -9.91%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $9.78
Upside: +22.70%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $636.30
Upside: +0.58%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $139.77
Upside: +3.74%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $55.66
Upside: -